Structured around discovery of life-saving interventions in critical illnesses due to a broad range of causes such as injuries resulting from warfare, major motor vehicle collisions or septic shock,Vivacelle Bio has a pipeline of products based upon its transformational phospholipid nanotechnology. Usefully understood as a developmental stage biotechnology company, Vivacelle Bio Inc's initial product - VBI-1 - is colloid non-blood volume expander potentially safer (and more effective) in animal studies than standard treatment for hypovolemia. Results to date have enabled an FDA green light to start a phase IIa clinical trial in hypovolemia due to blood loss. Second product (VBI-S) in the pipeline targets hypovolemia due to sepsis/septic shock - a consequence of inadequate fluid volume in the blood vessels (designated Hypovolemia) involves annually the death of over a one million people globally. Major causes for fluid loss are trauma, surgery, shock, sepsis, severe diarrhea and burns. Inadequate circulating volume impairs tissue perfusion and oxygenation leading to cell injury and death. Rapid volume replacement and re-establishment of normal blood pressure are essential for survival. Currently available options of fluid replacements are non-blood volume expanders (colloids and crystalloids), blood products and blood substitutes. These have largely proven to be impractical while also having the potential for significant negative adverse effects. VBI-1, represents a new paradigm in fluid resuscitation, safely restoring blood vessel volume and reversing the effects of hypovolemia. VBI-1 also modulates Nitric Oxide -- a potent vasodilator that drops the blood pressure and a precursor to highly highly toxic mediators -- , reduces reperfusion injury, inhibits the inflammatory response, clears the endotoxin, metabolizes to naturally-occurring components and acts as an energy source. In addition, it can be loaded with readily available oxygen. In the early days of Covid (Nov 2020) Vivacelle was awarded $5.3M by the US Navy for a Clinical Trial of VBI-S for Treatment of Hypovolemia of Septic Shock Due to COVID or other Pathogens
